DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)

Information source: Hospital for Special Surgery, New York
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Osteoarthritis

Intervention: Bupivacaine (Drug); Morphine (Drug); Methylprednisolone (Drug); Cefazolin (Drug); Normal saline (Drug); Midazolam (Drug); Propofol (Drug); Dexamethasone (Drug); 8 MHz. Chiba needle, 22 G / 4 inches (Device)

Phase: Phase 4

Status: Recruiting

Sponsored by: Hospital for Special Surgery, New York

Overall contact:
Jennifer Cheng, PhD, Phone: 212-774-7377, Email: ChengJ@hss.edu

Summary

Total knee replacement is associated with severe post-operative pain. The purpose of this study is to compare two methods of treatment for pain control following Total Knee Replacement with an accelerated physical therapy protocol to aid the achievement of rehab milestones.

Clinical Details

Official title: The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Primary outcome: Time to Meet Physical Therapy Discharge Criteria

Secondary outcome:

Numerial Rating Scale (NRS) Pain Scores

Opioid Consumption

Hospital Length of Stay

Patient Outcome Questionnaire (painOUT)

Knee Society Score (KSS)

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients with osteoarthritis scheduled for primary tricompartmental total knee

arthroplasty with a participating surgeon

- Age 18 to 80 years

- Planned use of regional anesthesia

- Ability to follow study protocol

- English speaking (secondary outcomes include questionnaires validated in English

only) Exclusion Criteria: Hepatic or renal insufficiency Patients younger than 18 years old and older than 80 Patients intending to receive general anesthesia Patients planning to go to rehab post operatively Patients scheduled to go into the OR after 1 pm Allergy or intolerance to one of the study medications Patients with an ASA of IV Chronic gabapentin/pregabalin use (regular use for longer than 3 months) Chronic opioid use (taking opioids for longer than 3 months) Diabetes Patients on workers compensation or disability

Locations and Contacts

Jennifer Cheng, PhD, Phone: 212-774-7377, Email: ChengJ@hss.edu

Hospital for Special Surgery, New York, New York 10021, United States; Recruiting
Enrique Goytizolo, MD, Phone: 212-606-1036, Email: GoytizoloE@hss.edu
Sumudu Dehipawala, BS, Phone: 646-797-8536, Email: DehipawalaS@hss.edu
Enrique Goytizolo, MD, Principal Investigator
Additional Information

Starting date: November 2014
Last updated: March 31, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017